Histology and Cytology Market Updates : Projected to Surpass USD 22.2 Billion by 2032 ; CAGR of 11.9% from 2023-2032

Histology and Cytology Market Overview 2023 – 2032:

Allied Market Research published a report, titled, “Histology and Cytology Marketby Type of Examination (Histology and Cytology), Product (Instruments & Analysis Software System and Consumable & Reagents), Test Type (Microscopy Methods, Flow Cytometry, and Molecular Genetic Methods), Application (Drug Discovery & Designing, Clinical Diagnostics, and Academic Research), and End User (Pharma & Biotech Companies, CDMO, Diagnostic Laboratories, and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032“. According to the report, the global histology and cytology market generated $7.2 billion in 2022, and is anticipated to generate $22.2 billion by 2032, witnessing a CAGR of 11.9% from 2023 to 2032.

Request Sample Copy Histology and Cytology Market Forecast 2032
https://www.alliedmarketresearch.com/request-sample/A15397

What is Driving Histology and Cytology Market ?

Histology and cytology techniques play a pivotal role in diagnosing and monitoring various diseases. As highlighted in a 2022 article from the National Library of Medicine, an estimated 1,918,030 new cancer cases and 609,360 cancer-related deaths are projected in the United States, with lung cancer alone causing approximately 350 deaths daily, underscoring the need for precise diagnostic methods.

Moreover, continual advancements in histology and cytology techniques, such as automation, digital pathology, and molecular pathology, contribute to the expansion of the market. The aging population is also a significant factor, as it is often associated with a higher prevalence of illnesses requiring thorough histological and cytological examination. With the global population aging, there is expected to be a significant increase in demand for diagnostic services.

Additionally, the growing recognition of the importance of early disease detection, coupled with the implementation of screening programs, further fuels the growth of the histology and cytology market. Early detection not only improves treatment outcomes but also reduces healthcare costs. For example, according to the World Health Organization, by 2050, 80% of the elderly population will be residing in low- and middle-income countries, emphasizing the global need for accessible diagnostic services.

Recession Impact

• During economic downturns, governments and healthcare organizations often encounter budget limitations, leading to reduced healthcare spending. This impacts funding for medical research, including studies in histology and cytology, and results in delayed integration of advanced technologies.
• The recession prompts individuals to decrease discretionary spending, affecting their ability to afford regular health check-ups and screening procedures. Consequently, there is a decrease in the number of histological and cytological examinations conducted.
• Healthcare institutions postpone or reduce capital expenditures during recessions, affecting the acquisition of new histology and cytology equipment and slowing the adoption of advanced technologies in laboratories.
• Both public and private sources experience a decline in research funding during economic downturns. This decrease in funding could impede histology and cytology research projects, potentially delaying the development of innovative diagnostic tools and methodologies.

Want to Explore More, Connect to our Analyst –  https://www.alliedmarketresearch.com/connect-to-analyst/A15397 

Recent Developments in the Histology and Cytology Industry

• In November 2023, W&H is expanding its hygiene portfolio with the addition of a new Lexa Plus Class B sterilizer and a new, technologically advanced Assistina One maintenance device bringing added peace of mind to reprocessing and infection prevention for a dental practices workflow.
• In June 2023, Becton, Dickinson, and Company launched a new automated instrument that prepares samples for clinical diagnostics using flow cytometry, enabling a complete “walkaway” workflow solution designed to improve standardization and reproducibility in cellular diagnostics.
• In May 2023, Becton, Dickinson, and Company announced the worldwide commercial launch of new-to-world cell sorting instrument featuring two breakthrough technologies that enable researchers to uncover more detailed information about cells that was previously invisible in traditional flow cytometry experiments. BD FACSDiscover S8 Cell Sorter First to Combine Spectral Flow Cytometry with Real-Time Imaging Technology.
• In August 2022, Becton, Dickinson, and Company announced a collaboration agreement with Labcorp, a leading global life sciences company, creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases.
• In June 2022, F. Hoffmann-La Roche Ltd announced the launch of the BenchMark ULTRA PLUS system, its newest advanced tissue staining platform. The system enables quick and accurate test results, so clinicians make timely decisions regarding a patient’s care journey.
• In June 2022, Becton, Dickinson and Company announced that it is expected to introduce new cell sorting technology at the International Society for Advancement of Cytometry (ISAC) CYTO 2022 conference that enables researchers to see and sort cells at speeds never before possible, which creates the potential to transform research and cell-based therapeutic development across a range of fields such as virology and oncology, as well as numerous disease states.
• In February 2022, Becton, Dickinson, and Company announced it has completed the acquisition of Cytognos, specializing in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection and immune monitoring research for blood diseases.

Key Findings of the Study

• By type of examination, the cytology segment was the highest contributor to the histology and cytology industry in 2022.
• By product, the consumable and reagents segment was the highest contributor to the market in 2022. However, instruments and analysis software system segment is expected to register highest CAGR during the forecast period.
• By test type, the microscopy methods segment dominated the market in 2022. However, flow cytometry segment is expected to register highest CAGR during the forecast period.
• By application, the drug discovery and designing segment dominated the market in 2022. However, clinical diagnostics segment is expected to register highest CAGR during the forecast period.
• By end user, the pharma and biotech companies segment dominated the histology and cytology industry in 2022. However, CDMO segment is expected to register highest CAGR during the forecast period.
• On the basis of region, the North America accounted for the largest share in terms of revenue in 2022. However, the Asia-Pacific region is projected to exhibit the highest CAGR in the market during the forecast period.

Drive Your Business Growth Strategy  Purchase the Report for Key Insights!

Key Market Players

• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Sysmex Corporation
• Merck KGaA
• Hologic, Inc.
• Trivitron Healthcare Private Limited
• Koninklijke Philips N.V.
• Becton, Dickinson, and Company
• Thermo Fisher Scientific, Inc.

Other Trending Reports in Life Science Domain- 

U.S Iron Supplements Market https://www.alliedmarketresearch.com/us-iron-supplement-market-A209135

Fibrin Sealants Market https://www.alliedmarketresearch.com/fibrin-sealants-market-A31579

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact Us:

David Correa

1209 Orange Street, Corporation Trust Center,

Wilmington,

New Castle,

Delaware 19801 USA.

Toll Free: +1-800-792-5285| Int’l: +1-503-894-6022

UK: +44-845-528-1300| Hong Kong: +852-301-84916

help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.co